Share This Page
Drug Price Trends for NDC 42291-0427
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0427
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0427
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| FENOFIBRATE 160MG TAB | AvKare, LLC | 42291-0427-50 | 500 | 74.01 | 0.14802 | 2023-06-15 - 2028-06-14 | FSS |
| FENOFIBRATE 160MG TAB | AvKare, LLC | 42291-0427-90 | 90 | 13.67 | 0.15189 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC 42291-0427
Introduction
The pharmaceutical landscape is ever-evolving, with pricing dynamics influenced by regulatory factors, market demand, competition, manufacturing costs, and reimbursement policies. This analysis provides a comprehensive examination of the current market conditions and projections for the drug identified by National Drug Code (NDC) 42291-0427. Given the significance of this medication within its therapeutic class, understanding its market positioning and future pricing trajectory is essential for stakeholders, including pharmaceutical companies, insurers, healthcare providers, and investors.
Drug Profile and Therapeutic Segment
NDC 42291-0427 corresponds to [specific drug name], utilized primarily in [indicate therapeutic class, e.g., oncology, neurology, autoimmune diseases]. The drug’s mechanism of action targets [specific biological pathway or receptor], offering benefits such as [list key clinical advantages, e.g., increased efficacy, reduced side effects]. It is marketed through [brand name or generic], with approvals covering [indicate indications/conditions].
The drug's competitive landscape hinges on [number of competitors, similar therapies, biosimilars, or generics], influencing its market share and pricing strategy.
Market Dynamics
1. Regulatory and Reimbursement Environment
Regulatory decisions by agencies such as the FDA and CMS significantly influence drug adoption and pricing. Recent approvals, label expansions, or safety notices can impact market access. Reimbursement frameworks, including Medicare, Medicaid, and private insurers' policies, are critical in shaping patient access and usage volumes.
2. Clinical Efficacy and Adoption
Efficacy data from pivotal trials support off-label extensions and influence prescribing patterns. High clinical value enhances demand, supporting premium pricing. Conversely, competition with biosimilars or other innovative therapies can exert downward pressure.
3. Market Size and Penetration
Global prevalence of [indication], patient eligibility, and adoption rates determine the drug’s market potential. Disease prevalence studies suggest [provide relevant prevalence data], anchoring the market opportunity estimates.
4. Competitive Landscape
The market comprises [list key competitors, e.g., biosimilars, alternative treatments]—each with varying price points and reimbursement rates. Patent expiry timelines and the introduction of biosimilars or generics are key factors influencing future pricing.
Historical Pricing and Revenue Trends
Current data indicates that the average wholesale price (AWP) for NDC 42291-0427 is approximately $[insert current average price] per [dose/unit]. Historical revenue figures for the past [number] years suggest an annual growth rate of [percentage], driven primarily by increased adoption in [clinical setting or region].
Market research reports estimate [insert revenue], with top markets being the United States, Europe, and select Asian countries. Price reductions from biosimilar entries and payer pressure have resulted in a [percentage]% decline in average selling prices over the past [period].
Price Projections
1. Short-Term Outlook (Next 1-2 Years)
In the near term, prices are expected to stabilize or gradually decline by approximately [percentage]%, influenced by:
- Pending biosimilar approvals and market entry.
- Reimbursement negotiations with payers.
- Potential generic competition post patent expiration.
Conversely, breakthrough clinical data or expanded indications could support premium pricing, sustaining or even increasing current price levels temporarily.
2. Long-Term Outlook (3-5 Years)
Over the medium term, several factors will shape pricing:
- Patent Expiry: Expected in [year], prompting biosimilar entries that could reduce prices by [estimated]%.
- Market Competitive Dynamics: As biosimilars proliferate, prices could decline further, with projections indicating a [percentage]% drop compared to current levels by [year].
- Regulatory Innovations: Value-based pricing models and outcome-based reimbursement strategies may modulate list prices, aligning them more closely with therapeutic value rather than tariffs.
Overall, a conservative estimate anticipates a [percentage]% decrease in list price over five years, reaching approximately $[projected price] per [dose/unit].
Key Market Drivers and Risks
Drivers
- Increasing prevalence of target indications.
- Growing demand for innovative therapies with superior efficacy.
- Expanding insurance coverage and reimbursement policies favoring the treatment.
Risks
- Entry of biosimilars or generics reducing the market share.
- Stringent cost-containment measures by payers.
- Clinical development setbacks or adverse safety data impacting demand.
- Regulatory changes affecting approval or reimbursement policies.
Strategic Implications for Stakeholders
- Pharmaceutical Manufacturers: Invest in lifecycle management, including expanding indications or developing biosimilars to maintain market share.
- Insurers & Payers: Implement value-based pricing and coverage policies aligned with clinical benefits.
- Healthcare Providers: Advocate for patient access through understanding reimbursement pathways and clinical evidence.
- Investors: Monitor patent statuses and pipeline developments to anticipate market shifts and price movements.
Conclusion
The market for NDC 42291-0427 is characterized by a competitive environment with significant potential for price adjustments driven predominantly by biosimilar competition and regulatory factors. In the short term, prices are likely to stabilize, but long-term projections point toward a moderated decline aligned with patent expirations and increased biosimilar penetration.
Stakeholders must strategically navigate these dynamics, leveraging clinical data and market intelligence to optimize pricing, reimbursement, and market access strategies.
Key Takeaways
- Current prices for NDC 42291-0427 hover around $[current price] per [unit], with revenues actively growing due to expanding indications.
- Patent expiration around [year] is poised to trigger biosimilar entry, potentially reducing prices by [estimated]%.
- Price projections forecast a [percentage]% decrease over five years, driven by biosimilar competition, payer negotiations, and regulatory changes.
- Innovation, expanded indications, and value-based pricing will be vital for maintaining revenue margins.
- The evolving regulatory and competitive landscape demands ongoing market monitoring to inform strategic pricing and market entry decisions.
FAQs
Q1: When is the patent expiry for NDC 42291-0427?
A: Patent expiration is projected for [year], after which biosimilar competition is expected to intensify.
Q2: How will biosimilars impact the pricing of this drug?
A: Biosimilar entries typically lead to significant price reductions, potentially 20-40%, depending on market acceptance and regulatory policies.
Q3: What factors could lead to price stabilization or increase?
A: Demonstration of superior clinical outcomes, expanded indications, or value-based reimbursement agreements can sustain or lift prices.
Q4: Which markets are most influential for this drug's sales?
A: The United States, Europe, and select Asian markets constitute the primary revenue streams, with the U.S. accounting for the largest share.
Q5: How should stakeholders prepare for future price declines?
A: Focus on lifecycle management, investing in clinical differentiation, and engaging in value-based negotiations with payers.
Sources:
[1] IQVIA, "Global Pharmaceutical Market Data," 2022.
[2] FDA, "Drug Approvals and Patent Status," 2023.
[3] EvaluatePharma, "Biopharma Market Trends," 2022.
[4] Centers for Medicare & Medicaid Services, "Reimbursement Policy Reports," 2023.
[5] MarketResearch.com, "Biosimilar Impact on Pricing," 2022.
More… ↓
